Enteric fever, commonly known as typhoid fever, is a systemic infection primarily caused by Salmonella Typhi or Salmonella Paratyphi. Despite advances in healthcare, it remains a significant public health issue, especially in developing countries. Early diagnosis and effective management are critical in reducing morbidity and mortality associated with the disease.
Diagnosis of enteric fever relies on clinical presentation, culture techniques, and serological tests. Clinical suspicion should be high in patients presenting with prolonged fever, abdominal pain, and constipation or diarrhea. Blood cultures remain the gold standard for diagnosis, with a sensitivity of 40-60%. However, their utility is limited by the necessity of specialized equipment and trained staff. Serological tests, such as the Widal test, offer a more accessible alternative but suffer from low specificity and sensitivity.
Recent advances have aimed at improving diagnostic accuracy and speed. Polymerase chain reaction (PCR) techniques targeting specific genes of Salmonella Typhi and Paratyphi have shown promising results. Rapid diagnostic tests (RDTs) based on the detection of specific antigens or antibodies are also being developed and evaluated.
Management of enteric fever involves both supportive care and antibiotic therapy. Fluid and electrolyte management is crucial in patients with severe disease. Antibiotic choice should be guided by local susceptibility patterns. Empiric therapy with a third-generation cephalosporin or fluoroquinolone is often initiated until culture results are available. In the case of drug-resistant strains, newer agents like azithromycin have shown efficacy.
In conclusion, enteric fever remains a significant health challenge necessitating prompt diagnosis and effective management. Advancements in diagnostic techniques and the judicious use of antibiotics are vital in reducing the disease burden. Continued research and development into improved diagnostic tools and therapeutic strategies are crucial in the fight against this enduring disease.
1.
Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup
2.
Olaparib-Abiraterone in mCRPCs Selected by Biomarkers Outperforms Each Agent by Itself.
3.
Top 10 questions about breast cancer answered
4.
Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study
5.
For some patients with bladder cancer that has invaded the muscle, trimodality therapy is just as effective as radical cystectomy.
1.
Single-Cell Lineage Tracing in Hematology: Decoding the Cellular Blueprint of Blood Disorders
2.
Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells
3.
Cancer Vaccines in Solid Tumors: Current Landscape, Mechanisms, and Clinical Implications
4.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
5.
Intratumoral Drug Distribution as a Determinant of Therapeutic Success
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
3.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation